Amresh Raina, MD, is director of the Advanced Heart Failure and Pulmonary Hypertension Program at Allegheny General Hospital and the Allegheny Health Network in Pittsburgh, Pennsylvania.
Amresh Raina, MD, is director of the advanced heart failure and pulmonary hypertension program at Allegheny General Hospital and the Allegheny Health Network in Pittsburgh, Pennsylvania. He is board-certified in advanced heart failure, echocardiography (imaging of the right ventricle), and general cardiology.
Transcript
How do the pathophysiologies of heart failure and chronically elevated pulmonary pressure intersect?
That’s a very interesting question. Pulmonary hypertension, first of all, is a broad term, saying that the pulmonary artery pressures—the pressures in the blood vessels of the lungs—are elevated, but doesn’t really say why they’re elevated. And so the first thing to note is that there are multiple different reasons and pathophysiologies at work in the development of pulmonary hypertension.
There are specific forms of pulmonary hypertension that are related to elevated resistance in the blood vessels of the lungs, and those are pulmonary arterial hypertension—we call that WHO [World Health Organization] Group 1, as well as chronic thromboembolic pulmonary hypertension, [and] that’s WHO Group 4. Those are diseases that lead to elevation and resistance in the blood vessels of the lungs, narrowing and constriction of the blood vessels. That elevates the pulmonary artery pressures, but also causes the right side of the heart to have to work harder to overcome that resistance and those pressures. And that can lead to right-sided congestive heart failure, symptoms of shortness of breath, swelling in the lower extremities, etc.
However, there are other forms of congestive heart failure that can cause pulmonary hypertension. Patients who have left-sided congestive heart failure, whether that’s due to lower left ventricular ejection fraction—what we call heart failure with reduced ejection fraction—or in patients who have heart failure symptoms but preserved left ventricular ejection fraction, both of those entities can cause elevation in pressures on the left side of the heart and that pressure can back up into the lungs and cause secondary pulmonary hypertension. That’s a different group of pulmonary hypertension, which we call related to left heart disease or WHO Group 2.
So, pulmonary hypertension can be the disease in and of itself, impacting the right side of the heart, or it can be a manifestation of a left-sided heart problem.
Dr. Raina is a nationally renowned physician with expertise in the diagnostic evaluation and management of pulmonary hypertension. His particular interest is in advanced imaging of the right ventricle in pulmonary arterial hypertension. He has published extensively in this field, with numerous peer-reviewed manuscripts, abstracts, and book chapters. Dr. Raina was named one of Pittsburgh Magazine's "Best Doctors" in 2019.
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Provisional CDC data show that US babies gained roughly a year in life expectancy in 2022; study findings indicate that the COVID-19 pandemic significantly raised the risk of preterm birth for expectant California mothers; New York Attorney General Letitia James said about 4 million New Yorkers were affected by a data breach of the medical transcription company Perry Johnson & Associates.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Gene Therapy Success in UK Likely Depends on Overcoming Education, Psychological Support Challenges
November 27th 2023Education, psychological support, and implementation guidance are the top unmet needs identified by investigators from the United Kingdom concerning gene therapy use for hemophilia.
Read More